Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells

William Gruenloh, Amal Kambal, Claus Sondergaard, Jeannine McGee, Catherine Nacey, Stefanos Kalomoiris, Karen Pepper, Scott Olson, Fernando A Fierro, Jan Nolta

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Mesenchymal stem cells (MSCs) have been shown to contribute to the recovery of tissues through homing to injured areas, especially to hypoxic, apoptotic, or inflamed areas and releasing factors that hasten endogenous repair. In some cases genetic engineering of the MSC is desired, since they are excellent delivery vehicles. We have derived MSCs from the human embryonic stem cell (hESC) line H9 (H9-MSCs). They expressed CD105, CD90, CD73, and CD146, and lacked expression of CD45, CD34, CD14, CD31, and HLA-DR, the hESC pluripotency markers SSEA-4 and Tra-1-81, and the hESC early differentiation marker SSEA-1. Marrow-derived MSCs showed a similar phenotype. H9-MSCs did not form teratoma in our initial studies, whereas the parent H9 line did so robustly. H9-MSCs differentiated into bone, cartilage, and adipocytes in vitro, and displayed increased migration under hypoxic conditions. Finally, using a hindlimb ischemia model, H9-MSCs were shown to home to the hypoxic muscle, but not the contralateral limb, by 48h after IV injection. In summary, we have defined methods for differentiation of hESCs into MSCs and have defined their characteristics and in vivo migratory properties.

Original languageEnglish (US)
Pages (from-to)1517-1525
Number of pages9
JournalTissue Engineering - Part A
Volume17
Issue number11-12
DOIs
StatePublished - Jun 1 2011

Fingerprint

Stem cells
Mesenchymal Stromal Cells
Testing
CD15 Antigens
Human Embryonic Stem Cells
Genetic Engineering
Differentiation Antigens
Teratoma
HLA-DR Antigens
Hindlimb
Adipocytes
Genetic engineering
Cartilage
Cell Differentiation
Ischemia
Extremities
Bone Marrow
Phenotype
Muscle
Bone and Bones

ASJC Scopus subject areas

  • Bioengineering
  • Biochemistry
  • Biomedical Engineering
  • Biomaterials
  • Medicine(all)

Cite this

Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells. / Gruenloh, William; Kambal, Amal; Sondergaard, Claus; McGee, Jeannine; Nacey, Catherine; Kalomoiris, Stefanos; Pepper, Karen; Olson, Scott; Fierro, Fernando A; Nolta, Jan.

In: Tissue Engineering - Part A, Vol. 17, No. 11-12, 01.06.2011, p. 1517-1525.

Research output: Contribution to journalArticle

Gruenloh, W, Kambal, A, Sondergaard, C, McGee, J, Nacey, C, Kalomoiris, S, Pepper, K, Olson, S, Fierro, FA & Nolta, J 2011, 'Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells', Tissue Engineering - Part A, vol. 17, no. 11-12, pp. 1517-1525. https://doi.org/10.1089/ten.tea.2010.0460
Gruenloh, William ; Kambal, Amal ; Sondergaard, Claus ; McGee, Jeannine ; Nacey, Catherine ; Kalomoiris, Stefanos ; Pepper, Karen ; Olson, Scott ; Fierro, Fernando A ; Nolta, Jan. / Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells. In: Tissue Engineering - Part A. 2011 ; Vol. 17, No. 11-12. pp. 1517-1525.
@article{0679c173c6a7471db4251c448dfe91c0,
title = "Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells",
abstract = "Mesenchymal stem cells (MSCs) have been shown to contribute to the recovery of tissues through homing to injured areas, especially to hypoxic, apoptotic, or inflamed areas and releasing factors that hasten endogenous repair. In some cases genetic engineering of the MSC is desired, since they are excellent delivery vehicles. We have derived MSCs from the human embryonic stem cell (hESC) line H9 (H9-MSCs). They expressed CD105, CD90, CD73, and CD146, and lacked expression of CD45, CD34, CD14, CD31, and HLA-DR, the hESC pluripotency markers SSEA-4 and Tra-1-81, and the hESC early differentiation marker SSEA-1. Marrow-derived MSCs showed a similar phenotype. H9-MSCs did not form teratoma in our initial studies, whereas the parent H9 line did so robustly. H9-MSCs differentiated into bone, cartilage, and adipocytes in vitro, and displayed increased migration under hypoxic conditions. Finally, using a hindlimb ischemia model, H9-MSCs were shown to home to the hypoxic muscle, but not the contralateral limb, by 48h after IV injection. In summary, we have defined methods for differentiation of hESCs into MSCs and have defined their characteristics and in vivo migratory properties.",
author = "William Gruenloh and Amal Kambal and Claus Sondergaard and Jeannine McGee and Catherine Nacey and Stefanos Kalomoiris and Karen Pepper and Scott Olson and Fierro, {Fernando A} and Jan Nolta",
year = "2011",
month = "6",
day = "1",
doi = "10.1089/ten.tea.2010.0460",
language = "English (US)",
volume = "17",
pages = "1517--1525",
journal = "Tissue Engineering - Part A",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "11-12",

}

TY - JOUR

T1 - Characterization and in vivo testing of mesenchymal stem cells derived from human embryonic stem cells

AU - Gruenloh, William

AU - Kambal, Amal

AU - Sondergaard, Claus

AU - McGee, Jeannine

AU - Nacey, Catherine

AU - Kalomoiris, Stefanos

AU - Pepper, Karen

AU - Olson, Scott

AU - Fierro, Fernando A

AU - Nolta, Jan

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Mesenchymal stem cells (MSCs) have been shown to contribute to the recovery of tissues through homing to injured areas, especially to hypoxic, apoptotic, or inflamed areas and releasing factors that hasten endogenous repair. In some cases genetic engineering of the MSC is desired, since they are excellent delivery vehicles. We have derived MSCs from the human embryonic stem cell (hESC) line H9 (H9-MSCs). They expressed CD105, CD90, CD73, and CD146, and lacked expression of CD45, CD34, CD14, CD31, and HLA-DR, the hESC pluripotency markers SSEA-4 and Tra-1-81, and the hESC early differentiation marker SSEA-1. Marrow-derived MSCs showed a similar phenotype. H9-MSCs did not form teratoma in our initial studies, whereas the parent H9 line did so robustly. H9-MSCs differentiated into bone, cartilage, and adipocytes in vitro, and displayed increased migration under hypoxic conditions. Finally, using a hindlimb ischemia model, H9-MSCs were shown to home to the hypoxic muscle, but not the contralateral limb, by 48h after IV injection. In summary, we have defined methods for differentiation of hESCs into MSCs and have defined their characteristics and in vivo migratory properties.

AB - Mesenchymal stem cells (MSCs) have been shown to contribute to the recovery of tissues through homing to injured areas, especially to hypoxic, apoptotic, or inflamed areas and releasing factors that hasten endogenous repair. In some cases genetic engineering of the MSC is desired, since they are excellent delivery vehicles. We have derived MSCs from the human embryonic stem cell (hESC) line H9 (H9-MSCs). They expressed CD105, CD90, CD73, and CD146, and lacked expression of CD45, CD34, CD14, CD31, and HLA-DR, the hESC pluripotency markers SSEA-4 and Tra-1-81, and the hESC early differentiation marker SSEA-1. Marrow-derived MSCs showed a similar phenotype. H9-MSCs did not form teratoma in our initial studies, whereas the parent H9 line did so robustly. H9-MSCs differentiated into bone, cartilage, and adipocytes in vitro, and displayed increased migration under hypoxic conditions. Finally, using a hindlimb ischemia model, H9-MSCs were shown to home to the hypoxic muscle, but not the contralateral limb, by 48h after IV injection. In summary, we have defined methods for differentiation of hESCs into MSCs and have defined their characteristics and in vivo migratory properties.

UR - http://www.scopus.com/inward/record.url?scp=79957602085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957602085&partnerID=8YFLogxK

U2 - 10.1089/ten.tea.2010.0460

DO - 10.1089/ten.tea.2010.0460

M3 - Article

C2 - 21275830

AN - SCOPUS:79957602085

VL - 17

SP - 1517

EP - 1525

JO - Tissue Engineering - Part A

JF - Tissue Engineering - Part A

SN - 1937-3341

IS - 11-12

ER -